Envista price target lowered to $17 from $19 at Baird

Baird analyst Jeff Johnson lowered the firm’s price target on Envista to $17 from $19 and keeps a Neutral rating on the shares. With dental stocks underperforming the S&P 500 by 20 points year-to-date, “a lot of bad is clearly priced into the group,” the analyst tells investors in a research note. The firm says that while dental fundamentals remain challenging, investor sentiment “feels even more negative.” It believes “now is the time to tip-toe back into dental.”